Nanoceria provides antioxidant and osteogenic properties to mesoporous silica nanoparticles for osteoporosis treatment

被引:63
|
作者
Pinna, Alessandra [1 ]
Baghbaderani, Mohammad Torki [1 ]
Hernandez, Victoria Vigil [1 ]
Naruphontjirakul, Parichart [2 ]
Li, Siwei [1 ]
McFarlane, Taneisha [1 ]
Hachim, Daniel [1 ]
Stevens, Molly M. [1 ,3 ,4 ]
Porter, Alexandra E. [1 ]
Jones, Julian R. [1 ]
机构
[1] Imperial Coll London, Dept Mat, South Kensington Campus, London SW7 2AZ, England
[2] King Mongkuts Univ Technol Thonburi, Biol Engn Program, Bangkok, Thailand
[3] Imperial Coll London, Dept Bioengn, South Kensington Campus, London SW7 2AZ, England
[4] Imperial Coll London, Inst Biomed Engn, South Kensington Campus, London SW7 2AZ, England
基金
英国工程与自然科学研究理事会; 欧盟地平线“2020”;
关键词
Nanoparticles; Radical scavengers; Osteoporosis; Bioactive glass; Nanoceria; CERIUM OXIDE NANOPARTICLES; BONE-MINERAL DENSITY; PRIMARY OSTEOBLASTS; OXIDATIVE STRESS; DIFFERENTIATION; BISPHOSPHONATES; CELLS; MECHANISM; GROWTH;
D O I
10.1016/j.actbio.2020.12.029
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Osteoporosis, a chronic metabolic bone disease, is the most common cause of fractures. Drugs for treating osteoporosis generally inhibit osteoclast (OC) activity, but are rarely aimed at encouraging new bone growth and often cause severe systemic side effects. Reactive oxygen species (ROS) are one of the key triggers of osteoporosis, by inducing osteoblast (OB) and osteocyte apoptosis and promoting osteoclastogenesis. Here we tested the capability of the ROS-scavenger nanoceria encapsulated within mesoporous silica nanoparticles (Ce@MSNs) to treat osteoporosis using a pre-osteoblast MC3T3-E1 cell monoculture in stressed and normal conditions. Ce@MSNs (diameter of 80 +/- 10 nm) were synthesised following a scalable two-step process involving sol-gel and wet impregnation methods. The Ce@MSNs at concentration of 100 mu g mL(-1) induced a significant reduction in oxidative stress produced by t-butyl hydroperoxide and did not alter cell viability significantly. Confocal microscopy showed that MSNs and Ce@MsNs were internalised into the cytoplasm of the pre-osteoblasts after 24 h but were not in the nucleus, avoiding any DNA and RNA modifications. Ce@MSNs provoked mineralisation of the pre-osteoablasts without osteogenic supplements, which did not occur when the cells were exposed to MSN without nanoceria. In a co-culture system of MC3T3-E1 and RAW264.7 macrophages, the Ce@MSNs exhibited antioxidant capability and stimulated cell proliferation and osteogenic responses without adding osteogenic supplements to the culture. The work brings forward an effective platform based for facile synthesis of Ce@MSNs to interact with both OBs and OCs for treatment of osteoporosis. Statement of significance Current therapies that treat osteoporosis only target osteoclasts (OCs), using drugs, leading to side effects. Here, new multicomponent 80 nm spherical nanoparticles (Ce@MSNs) combine antioxidant, osteogenic and anti-osteoclastogenic properties. Ce@MSNs interact with both osteoblast (OBs) and OCs in co-culture of osteoblasts and macrophages. Ce@MSNs stimulated osteoblast cells to produce bone matrix and demonstrated antioxidant properties in a co-culture cells without osteogenic supplements. Ce@MSNs have potential for treating osteoporosis and they could be adapted Ce@MSNs for the treatment of other diseases caused by oxidative stress. (C) 2020 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:365 / 376
页数:12
相关论文
共 50 条
  • [1] Thiol-Functionalized, Antioxidant, and Osteogenic Mesoporous Silica Nanoparticles for Osteoporosis
    Rasool, Nahida
    Negi, Deepa
    Singh, Yashveer
    ACS BIOMATERIALS SCIENCE & ENGINEERING, 2023, 9 (06): : 3535 - 3545
  • [2] Mesoporous silica nanoparticles and osteoporosis
    Manzano, M.
    Lozano, D.
    Vallet-Regi, M.
    REVISTA DE OSTEOPOROSIS Y METABOLISMO MINERAL, 2022, 14 (04) : 101 - 103
  • [3] Pleiotrophin-Loaded Mesoporous Silica Nanoparticles as a Possible Treatment for Osteoporosis
    Lozano, Daniel
    Leiva, Beatriz
    Gomez-Escalonilla, Ines S.
    Portal-Nunez, Sergio
    de Gortazar, Arancha R.
    Manzano, Miguel
    Vallet-Regi, Maria
    PHARMACEUTICS, 2023, 15 (02)
  • [4] Thiolated mesoporous silica nanoparticles for the treatment of oxidative stress-associated osteoporosis
    Dar, Nahida Rasool
    Singh, Yashveer
    TISSUE ENGINEERING PART A, 2022, 28 : 666 - 666
  • [5] Osteoporosis Remission and New Bone Formation with Mesoporous Silica Nanoparticles
    Mora-Raimundo, Patricia
    Lozano, Daniel
    Benito, Manuel
    Mulero, Francisca
    Manzano, Miguel
    Vallet-Regi, Maria
    ADVANCED SCIENCE, 2021, 8 (16)
  • [6] Mesoporous Silica Nanoparticles for the Treatment of Complex Bone Diseases: Bone Cancer, Bone Infection and Osteoporosis
    Gisbert-Garzaran, Miguel
    Manzano, Miguel
    Vallet-Regi, Maria
    PHARMACEUTICS, 2020, 12 (01)
  • [7] Magnetic properties of iron nanoparticles in mesoporous silica
    Kelberg, E. A.
    Grigoriev, S. V.
    Okorokov, A. I.
    Eckerlebe, H.
    Grigorieva, N. A.
    Eliseev, A. A.
    Lukashin, A. V.
    Vertegel, A. A.
    Napolskii, K. S.
    PHYSICA B-CONDENSED MATTER, 2004, 350 (1-3) : E305 - E308
  • [8] Antioxidant properties of probucol released from mesoporous silica
    Lau, Michael
    Giri, Kalpeshkumar
    Garcia-Bennett, Alfonso E.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 138
  • [9] Alendronate decorated nano hydroxyapatite in mesoporous silica: Cytotoxicity and osteogenic properties
    Huang, Wei
    Liu, Weiqiang
    She, Zhending
    Wu, Hongkai
    Shi, Xuetao
    APPLIED SURFACE SCIENCE, 2011, 257 (23) : 9757 - 9761
  • [10] Antioxidant and antimicrobial activity of red propolis embedded mesoporous silica nanoparticles
    Oliveira, Lais F. Azevedo de M.
    de Azevedo Teles da Silva, Lais Vanessa
    do Nascimento, Ticiano G.
    de Almeida, Lara Mendes
    Nunes Calumby, Rodrigo Jose
    Nunes, Abner Magalhaes
    Tenorio de Magalhaes Oliveira, Leonardo Mendonca
    da Silva Fonseca, Eduardo J.
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2020, 46 (07) : 1199 - 1208